Acumen Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -46 | -45 | ||
EBITDA | -24,358 | -31,579 | -19,622 | -24,006 |
EBIT | -24,370 | -31,624 | -19,668 | -24,051 |
Net Income | -25,369 | -32,718 | -20,737 | -25,138 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -26,653 | -18,075 | -24,128 | -19,096 |
Cash | 53,075 | 59,443 | 51,796 | 53,989 |
Basic Shares | 72,321 | 72,250 | 63,219 | 60,561 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -184 | -178 | -42,318 | -169 |
EBITDA | -116,927 | -98,083 | -51,606 | -42,687 |
EBIT | -117,111 | -98,261 | -51,790 | -42,856 |
Net Income | -121,335 | -102,329 | -52,371 | -42,856 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | 7,939 | |||
Free Cash Flow | -115,626 | -86,231 | -43,085 | -35,314 |
Cash | 53,989 | 35,627 | 66,886 | 130,101 |
Basic Shares | 60,561 | 60,013 | 48,609 | 40,601 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$0.35 |
2026-06-30 | -$0.45 |
2026-03-31 | -$0.33 |
2025-12-31 | -$0.41 |